| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STEAP1 |
| Uniprot No | Q9UHE8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-339aa |
| 氨基酸序列 | MESRKDITNQEELWKMKPRRNLEEDDYLHKDTGETSMLKRPVLLHLHQTAHADEFDCPSELQHTQELFPQWHLPIKIAAIIASLTFLYTLLREVIHPLATSHQQYFYKIPILVINKVLPMVSITLLALVYLPGVIAAIVQLHNGTKYKKFPHWLDKWMLTRKQFGLLSFFFAVLHAIYSLSYPMRRSYRYKLLNWAYQQVQQNKEDAWIEHDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSLTWREFHYIQSKLGIVSLLLGTIHALIFAWNKWIDIKQFVWYTPPTFMIAVFLPIVVLIFKSILFLPCLRKKILKIRHGWEDVTKINKTEICSQL |
| 预测分子量 | 41.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于STEAP1重组蛋白的文献摘要信息：
1. **文献名称**: "STEAP1 facilitates metastasis and epithelial-mesenchymal transition of lung adenocarcinoma via the JAK2/STAT3 signaling pathway"
**作者**: Zhang Y, et al.
**摘要**: 研究通过重组STEAP1蛋白验证其在肺癌转移中的作用，发现其通过激活JAK2/STAT3通路促进肿瘤细胞侵袭和上皮间质转化(EMT)。
2. **文献名称**: "STEAP1 is an iron reductase required for proper mitochondrial function and prostate cancer cell growth"
**作者**: Gomes IM, et al.
**摘要**: 利用重组STEAP1蛋白揭示其铁离子还原酶功能，证明其在维持线粒体活性和前列腺癌细胞增殖中的关键作用，为靶向治疗提供依据。
3. **文献名称**: "Development of a STEAP1-targeting monoclonal antibody for cancer immunotherapy"
**作者**: Lee JK, et al.
**摘要**: 研究通过重组STEAP1蛋白筛选特异性抗体，成功开发出靶向STEAP1的单克隆抗体，并在动物模型中验证其抑制肿瘤生长的免疫治疗效果。
4. **文献名称**: "Recombinant STEAP1 protein as a potential biomarker for prostate cancer diagnosis"
**作者**: Chen H, et al.
**摘要**: 通过重组STEAP1蛋白建立血清检测方法，发现其在前列腺癌患者中高表达，具有较高的诊断敏感性和特异性。
这些文献涵盖了STEAP1重组蛋白在肿瘤机制、治疗靶点及诊断应用中的研究。
**Background of STEAP1 Recombinant Protein**
STEAP1 (Six-transmembrane epithelial antigen of the prostate 1) is a member of the STEAP family of metalloreductases, initially identified for its overexpression in prostate cancer. It is a transmembrane protein with six helical domains, primarily localized to the plasma membrane and endocytic compartments. STEAP1 plays a role in metal ion homeostasis, particularly in the reduction of iron and copper, which are critical for cellular processes like electron transport and enzyme function. Its metalloreductase activity is linked to promoting cancer cell proliferation, survival, and metastasis.
STEAP1 is highly expressed in multiple cancers, including prostate, bladder, lung, and pancreatic cancers, while showing limited presence in normal tissues, making it a promising therapeutic target and diagnostic biomarker. Its involvement in oncogenic pathways and the tumor microenvironment has spurred interest in developing STEAP1-targeted therapies, such as antibodies, vaccines, and small-molecule inhibitors.
Recombinant STEAP1 protein is engineered using expression systems like mammalian or bacterial cells to produce purified, biologically active forms for research and drug development. This protein retains key structural and functional domains, enabling studies on its enzymatic mechanisms, interaction with antibodies, and role in cancer biology. Recombinant STEAP1 is widely used in immunoassays, antibody validation, and preclinical studies to evaluate targeting strategies. Its application also extends to understanding STEAP1’s immunogenicity, supporting the design of cancer immunotherapies.
Overall, STEAP1 recombinant protein serves as a vital tool in oncology research, bridging mechanistic insights with translational efforts to combat STEAP1-associated malignancies.
×
